Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

Background—The degree to which cytochrome P450 (CYP) 2C19 genotype influences the
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …

Objective To evaluate the accumulated information from genetic association studies
investigating the impact of variants of the cytochrome P450 (CYP) 2C19 genotype on the …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been
hypothesized to be associated with lesser degrees of platelet inhibition and increased risk …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Several studies have investigated the association between CYP2C19 polymorphism and
clinical outcomes of patients treated with clopidogrel, but few have noticed the difference in …